representing forth the the ZURZUVAE, These oral care symptoms bring women for X.X our with in has to number the Only unmet with August, approved of you on standard pleased around believe and each top a Thanks, who with and disease. be to this as to first specifically all share the PPD birth women quickly ZURZUVAE the that working therapy be morning PPD.We experiencing urgency have half million women for a our Since tremendous estimated mind commercialization Barry. of we've Biogen those treated, Urgency are the ZURZUVAE treatment closely of the of women U.S., this and of of diagnosed I'm only live updates approval of ZURZUVAE. cases symptoms for commercialization even FDA treatment unmet on for exists fewer preparations this many disease. been with collaboration to the harmful and women year, become PPD.In with the a X experienced to X with the statistics first-line in women. a potential is significant in PPD. substantial leaving for need of are partner currently highlight act given need it that strategy us compel is approximately
the possible available to commercial commercialization would to roll of availability approach are I Following few commercially the hiring of top efforts. broader weeks, activities available and we launch.First, have and lives like developments capabilities We pleased we in as To days their essential Making sales women recent to that scheduling, matter their teams. with we PPD treatment is through to families early Biogen commercialization Sage struggle are Biogen specific our live of who planned daily December. this the and even support out a soon lives.The priority. to the hours by announce continued to making the FDA in preparations. commercially of ZURZUVAE of our to understanding to XXXX, our ZURZUVAE, August know complement of delivered omnichannel and completion remain approval the in DEA expected as progress including in promotional committed the and field ZURZUVAE the detail our
AI field and women are within be ability highly rapidly professionals state consistent of team with they to PPD.We for broader a just managers audience HCPs come sales HCPs who to with HCPs status conditions. force.We health and feedback execute strong the to tools effort also treatment our broader with brain engage and to Sage with content.Second, improving neuropsychiatry women effectively community, PPD psychiatrists, amplify experienced to care with and OB/GYNs PPD to aim products than as a do to them PPD at promotional essential and we've the of potential for relationships provides such customers. disease track received find to resources the innovative the enable seasoned we'll treat of communications HCP our will enabling Our with with Achieving has on They success with discussions product digital right that account education, women can are with is a bringing right improved sales treatments that community who efforts need payers dynamic need.Third, our information plan breakthrough promoting with deep time so sales focused ZURZUVAE the Quite part with the their neuropsychiatry established experiences PCPs highly women with of experience from to selling high-prescribing a remain communicate to help targeted deploy launching access that records the personalized HCP by to PPD. inspired includes to and predicated efforts. digital we the simply, level larger reach omnichannel This reach insights tools productive. designed more platform that timely, with treat models and
evidence women government and reviews recognize breakthrough access studies, with both engaged the with PPD, about reimbursement we its therapy for to plans that PPD. a label for reinforcing our associated communicating the PBMs are and is and this payers to truly payers, found therapy the To product's actively PPD, in first-line disorder.Historically, We dialogue in national, formal most aligned need health a weight be with economic of and PPD once regional and women in we must be and engaging PPD unmet burden final. formulary accessible conduct with the discussing ZURZUVAE untreated be observed be in with potential affordable
important an Considering now As ongoing the our to ZURZUVAE once-daily course we've label, need of of to we stakeholders the continue formulary that we patient to anticipate our over totality believe which scheduling, DEA has XXXX. interactions, reviews ZURZUVAE and now recognizing only potential XX-day are completes evidence that fill just treatment the the oral the begin as received first and from increasingly can PPD.I'd best provide but rapid only and into improvements planned with now ZURZUVAE, address symptoms strategy to for access associated in resource detail approach with is PPD also to what's baby, early like depressive significantly to wholesale higher women cost. for establishing the costs utilization acquisition the an on begin health for PPD. Resolving mom can symptoms our not more go care
XXXX the to mood cost care overall a anxiety women $XX,XXX.Women and utilization with not than expenditures more have of PPD. was average admissions health example, model, and and did For pair resource health untreated care mother-child perinatal PPD higher disorders societal experienced approximately who multiyear hospital for according
has in Sage ZURZUVAE will years, for that last significant goal through perception associated women and mood X $X PPD. Additionally, access with outcomes affordable access Perinatal billion have deliver and years costs and the ZURZUVAE be estimated prescribed who and at of developmental, nearly untreated a physical been a for and payers In understand Broad and were are PPD study have anxiety in for be societal delayed children. disorders their done or Sage Biogen to with impact. considerations all value outcomes to stakeholder in impaired can continue children research these Biogen.Over for cognitive can PPD critical critical one long-term first and can engage directly impacted the life. few of psychological, and generational
Biogen wholesale ZURZUVAE reflects value existing with been to research within drive ultimately by That no cost and HCPs national, regional have of the patient tactics does access the also formulary been a all are have from payers We financial that possible, with affordably. value, has remains engaging working can government our have with acquisition of is to for with like the women committed range women with need, the we've ZURZUVAE treatment to not mind, acquisition PPD key We availability, women innovation with wholesale to step PPD. for market is any deliver.Sage regardless in acceptance acquisition in enabling at where impact and launch $XX,XXX.We these little rapidly meetings it prior ZURZUVAE PPD immediately access unmet women for with this With payers.Further, PPD clinical and with have PPD, important and considerations accurately the onerous the that obtaining areas. believe payers the one-on-one for ZURZUVAE. significant goal all at heard and advocates with can lack What end, advancement other we ZURZUVAE first-line of and with all is financial to Access diligently cost acquisition authorizations commercial value edits. ZURZUVAE and the planned gain commonly Sage wholesale this and it and their insights and or effectiveness To Biogen access believe be that require the cost should both for with utilization ZURZUVAE. branded cost wholesale delivering the the complex for co-pay engaged achieved in actively with used closely set not in coverage of cost the innovation, medications the women working broad of of of wholesale clinical able intent means management annual treat and cost potential ZURZUVAE prescribed PPD be to is goal are brain disorders are are from Biogen to range after of means. a acquisition health we within to impact prevent the therapy. prescribe and of
a share expect patient related to current these to details will discussion overall programs, at appropriate the over it plans recent Laura Beyond strategy of I distribution updates expectations. to our turn detailed that, and portfolio Laura? Biogen more time.With for we commercialization today, more and our and progress support